[1] |
Bauland CG, Lüning TH, Smit JM, et al. Untreated hemangiomas: growth pattern and residual lesions[J]. Plast Reconstr Surg, 2011,127(4):1643⁃1648. doi: 10.1097/PRS.0b013 e318208d2ac.
|
[2] |
Léauté⁃Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008,358(24):2649⁃2651. doi: 10.1056/NEJMc0708819.
|
[3] |
Babiak⁃Choroszczak L, Giżewska⁃Kacprzak K, Dawid G, et al. Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas[J]. Adv Clin Exp Med, 2019,28(3):375⁃384. doi: 10.17219/acem/94136.
|
[4] |
Léauté⁃Labrèze C, Hoeger P, Mazereeuw⁃Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma[J]. N Engl J Med, 2015,372(8):735⁃746. doi: 10. 1056/NEJMoa1404710.
|
[5] |
Marqueling AL, Oza V, Frieden IJ, et al. Propranolol and infantile hemangiomas four years later: a systematic review[J]. Pediatr Dermatol, 2013,30(2):182⁃191. doi: 10.1111/pde.12089.
|
[6] |
Li L, Wei L, Xu ZG, et al. No increased risks associated with propranolol treatment for infantile hemangioma in preterm infants were identified at 3 years of age[J]. Am J Clin Dermatol, 2019,20(2):289⁃293. doi: 10.1007/s40257⁃018⁃00419⁃1.
|
[7] |
López⁃Gutiérrez JC. Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol: overview of single⁃center experience from La Paz Hospital, Madrid[J]. Eur J Pediatr, 2019,178(1):1⁃6. doi: 10.1007/s00431⁃018⁃3290⁃z.
|
[8] |
Smithson SL, Rademaker M, Adams S, et al. Consensus statement for the treatment of infantile haemangiomas with propranolol[J]. Australas J Dermatol, 2017,58(2):155⁃159. doi: 10.1111/ajd.12600.
|
[9] |
Solman L, Glover M, Beattie PE, et al. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines[J]. Br J Dermatol, 2018,179(3):582⁃589. doi: 10.1111/bjd.16779.
|
[10] |
Baselga Torres E, Bernabéu Wittel J, van Esso Arbolave DL, et al. Spanish consensus on infantile haemangioma[J]. An Pediatr (Barc), 2016,85(5):256⁃265. doi: 10.1016/j.anpedi.2015.10.004.
|
[11] |
Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference[J]. Pediatrics, 2013,131(1):128⁃140. doi: 10.1542/peds.2012⁃1691.
|
[12] |
Hoeger PH, Harper JI, Baselga E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group[J]. Eur J Pediatr, 2015,174(7):855⁃865. doi: 10.1007/s00431⁃015⁃2570⁃0.
|
[13] |
中华医学会整形外科分会血管瘤和脉管畸形学组. 血管瘤和脉管畸形的诊断及治疗指南(2019版)[J]. 组织工程与重建外科杂志, 2019,15(5):277⁃317. doi: 10.3969/j.issn.1673⁃0364. 2019.05.001.
|
[14] |
Lee D, Boscolo E, Durham JT, et al. Propranolol targets the contractility of infantile haemangioma⁃derived pericytes[J]. Br J Dermatol, 2014,171(5):1129⁃1137. doi: 10.1111/bjd.13048.
|
[15] |
Pan WK, Li P, Guo ZT, et al. Propranolol induces regression of hemangioma cells via the down⁃regulation of the PI3K/Akt/eNOS/VEGF pathway[J]. Pediatr Blood Cancer, 2015,62(8):1414⁃1420. doi: 10.1002/pbc.25453.
|
[16] |
Yuan WL, Jin ZL, Wei JJ, et al. Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients[J]. Br J Oral Maxillofac Surg, 2013,51(7):656⁃661. doi: 10.1016/j.bjoms. 2012.12.003.
|
[17] |
Li D, Li P, Guo Z, et al. Downregulation of miR⁃382 by propranolol inhibits the progression of infantile hemangioma via the PTEN⁃mediated AKT/mTOR pathway[J]. Int J Mol Med, 2017,39(3):757⁃763. doi: 10.3892/ijmm.2017.2863.
|
[18] |
Lamy S, Lachambre MP, Lord⁃Dufour S, et al. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells[J]. Vascul Pharmacol, 2010,53(5⁃6):200⁃208. doi: 10.1016/j.vph.2010.08. 002.
|
[19] |
Ma X, Zhao T, Ouyang T, et al. Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells[J]. Int J Clin Exp Pathol, 2014,7(7):3809⁃3817.
|
[20] |
Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas[J]. Pediatrics, 2019,143(1):e20183475. doi: 10.1542/peds.2018⁃3475.
|
[21] |
Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management[J]. Pediatrics, 2008,122(2):360⁃367. doi: 10. 1542/peds.2007⁃2767.
|
[22] |
Yu Z, Cai R, Chang L, et al. Clinical and radiological outcomes of infantile hemangioma treated with oral propranolol: a long⁃term follow⁃up study[J]. J Dermatol, 2019,46(5):376⁃382. doi: 10.1111/1346⁃8138.14853.
|
[23] |
Onnis G, Dreyfus I, Mazereeuw⁃Hautier J. Factors associated with delayed referral for infantile hemangioma necessitating propranolol[J]. J Eur Acad Dermatol Venereol, 2018,32(9):1584⁃1588. doi: 10.1111/jdv.14842.
|
[24] |
Li L, Ma L. Use of propranolol on a nasal hemangioma in an extremely low birthweight premature infant[J]. J Dermatol, 2015,42(11):1101⁃1102. doi: 10.1111/1346⁃8138.13029.
|
[25] |
Brandling⁃Bennett HA, Metry DW, Baselga E, et al. Infantile hemangiomas with unusually prolonged growth phase: a case series[J]. Arch Dermatol, 2008,144(12):1632⁃1637. doi: 10. 1001/archderm.144.12.1632.
|
[26] |
Lamy S, Lachambre MP, Lord⁃Dufour S, et al. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells[J]. Vascul Pharmacol, 2010,53(5⁃6):200⁃208. doi: 10.1016/j.vph.2010.08. 002.
|
[27] |
Vivas⁃Colmenares GV, Bernabeu⁃Wittel J, Alonso⁃Arroyo V, et al. Effectiveness of propranolol in the treatment of infantile hemangioma beyond the proliferation phase[J]. Pediatr Dermatol, 2015,32(3):348⁃352. doi: 10.1111/pde.12520.
|
[28] |
Zvulunov A, McCuaig C, Frieden IJ, et al. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study[J]. Pediatr Dermatol, 2011,28(2):94⁃98. doi: 10.1111/j.1525⁃1470.2010.01379.x.
|
[29] |
Zhou HH, Koshakji RP, Silberstein DJ, et al. Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites[J]. N Engl J Med, 1989,320(9):565⁃570. doi: 10.1056/NEJM198903023200905.
|
[30] |
Zhou HH, Shay SD, Wood AJ. Contribution of differences in plasma binding of propranolol to ethnic differences in sensitivity. Comparison between Chinese and Caucasians[J]. Chin Med J (Engl), 1993,106(12):898⁃902.
|
[31] |
Fogel I, Ollech A, Zvulunov A, et al. Safety profile during initiation of propranolol for treatment of infantile haemangiomas in an ambulatory day⁃care hospitalization setting[J]. J Eur Acad Dermatol Venereol, 2018,32(11):2004⁃2009. doi: 10.1111/jdv. 14955.
|
[32] |
于鲁, 李丽, 马琳. 口服普萘洛尔治疗婴儿血管瘤的近期和远期安全性[J]. 中华皮肤科杂志, 2019,52(8):586⁃589. doi: 10.3760/cma.j.issn.0412⁃4030.2019.08.019.
|
[33] |
李丽, 徐子刚, 孙玉娟, 等. 普萘洛尔治疗婴儿血管瘤复发因素分析[J]. 中华皮肤科杂志, 2017,50(2):77⁃80. doi: 10.3760/cma.j.issn.0412⁃4030.2017.02.001.
|
[34] |
Bagazgoitia L, Hernández⁃Martín A, Torrelo A. Recurrence of infantile hemangiomas treated with propranolol[J]. Pediatr Dermatol, 2011,28(6):658⁃662. doi: 10.1111/j.1525⁃1470.2011. 01644.x.
|
[35] |
Baselga E, Dembowska⁃Baginska B, Przewratil P, et al. Efficacy of propranolol between 6 and 12 months of age in high⁃risk infantile hemangioma[J]. Pediatrics, 2018,142(3):e20173866. doi: 10.1542/peds.2017⁃3866.
|
[36] |
O′Brien KF, Shah SD, Pope E, et al. Late growth of infantile hemangiomas in children >3 years of age: a retrospective study[J]. J Am Acad Dermatol, 2019,80(2):493⁃499. doi: 10.1016/j.jaad.2018.07.061.
|
[37] |
Rangno RE, Nattel S, Lutterodt A. Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule[J]. Am J Cardiol, 1982,49(4):828⁃833. doi: 10.1016/0002⁃9149(82)91965⁃8.
|
[38] |
Love JN, Sikka N. Are 1⁃2 tablets dangerous? Beta⁃blocker exposure in toddlers[J]. J Emerg Med, 2004,26(3):309⁃314. doi: 10.1016/j.jemermed.2003.11.015.
|
[39] |
Gonski K, Wargon O. Retrospective follow up of gross motor development in children using propranolol for treatment of infantile haemangioma at Sydney Children′s Hospital[J]. Australas J Dermatol, 2014,55(3):209⁃211. doi: 10.1111/ajd. 12156.
|
[40] |
Moyakine AV, Hermans DJ, Fuijkschot J, et al. Propranolol treatment of infantile hemangiomas does not negatively affect psychomotor development[J]. J Am Acad Dermatol, 2015,73(2):341⁃342. doi: 10.1016/j.jaad.2015.04.053.
|
[41] |
Moyakine AV, Kerstjens JM, Spillekom⁃van Koulil S, et al. Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years[J]. J Am Acad Dermatol, 2016,75(1):59⁃63.e1. doi: 10.1016/j.jaad.2016.02.1218.
|
[42] |
刘笑宇, 李丽, 尉莉, 等. 2%卡替洛尔溶液局部治疗婴儿血管瘤的疗效及安全性研究[J]. 临床皮肤科杂志, 2017,46(01):68⁃70.
|
[43] |
李丽, 王华, 王榴慧, 等. 多磺酸黏多糖减少中、低风险婴儿血管瘤治疗后发生湿疹及皮肤萎缩的多中心研究[J]. 中华皮肤科杂志, 2019,52(10):779⁃784. doi: 10.35541/cjd.20190196.
|